VANCOUVER, British Columbia - In the world of cash-starved biotechs, particularly platform-based firms whose limited resources support only a sliver of the pipeline potential, many have sought partnerships or set themselves up as acquisition targets to maximize that potential. (BioWorld Financial Watch)

Rather than drafting a separate proposal about approval authority for follow-on biologics, the FDA has agreed to work with lawmakers on developing that legislation. (BioWorld Today)